![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 39/395 | (2006.01) |
C07K 16/30 | (2013.01) | ||
A61P 35/00 | (2006.01) | ||
A61K 39/39558 | (2013.01) | ||
C07K 16/30 | (2006.01) | ||
C07K 16/2803 | (2013.01) | ||
A61K 31/357 | (2006.01) | ||
C07K 16/2887 | (2013.01) | ||
A61P 35/02 | (2006.01) | ||
C07K 16/3007 | (2013.01) | ||
A61K2039/505 | (2013.01) | ||
A61P 35/04 | (2006.01) | ||
A61P 43/00 | (2006.01) | ||
A61K2039/545 | (2013.01) | ||
C07K 16/28 | (2006.01) | ||
C07K2317/24 | (2013.01) | ||
A61K 39/00 | (2006.01) | ||
C07K2317/73 | (2013.01) | ||
A61K 47/68 | (2017.01) | ||
C07K2317/732 | (2013.01) | ||
A61K 45/06 | (2006.01) | ||
C07K2317/94 | (2013.01) | ||
A61K 31/337 | (2006.01) | ||
A61K 47/6803 | (2017.08) | ||
A61K 31/502 | (2006.01) | ||
A61K 47/6849 | (2017.08) | ||
A61K 31/519 | (2006.01) | ||
A61K 47/6851 | (2017.08) | ||
A61K 31/52 | (2006.01) | ||
A61K 47/6853 | (2017.08) | ||
A61K 45/06 | (2013.01) | ||
A61K 31/337 | (2013.01) | ||
A61K 31/357 | (2013.01) | ||
A61K 31/502 | (2013.01) | ||
A61K 31/519 | (2013.01) | ||
A61K 31/52 | (2013.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 35/02 | (2018.01) | ||
A61P 35/04 | (2018.01) | ||
A61P 43/00 | (2018.01) |
(11) | Number of the document | 3313443 |
(13) | Kind of document | T |
(96) | European patent application number | 16815285.8 |
Date of filing the European patent application | 2016-06-23 | |
(97) | Date of publication of the European application | 2018-05-02 |
(45) | Date of publication and mention of the grant of the patent | 2023-06-07 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2016/038986 |
Date | 2016-06-23 |
(87) | Number | WO 2016/210108 |
Date | 2016-12-29 |
(30) | Number | Date | Country code |
201562184331 P | 2015-06-25 | US | |
201562201361 P | 2015-08-05 | US | |
201562250715 P | 2015-11-04 | US | |
201562263134 P | 2015-12-04 | US | |
201615069208 | 2016-03-14 | US |
(72) |
GOLDENBERG, David M. , US
CARDILLO, Thomas, M. , US
|
(73) |
Immunomedics, Inc. ,
300 American Road, Morris Plains, NJ 07950,
US
|
(54) | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER |
COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER |